Korean Post-marketing Surveillance for Kombiglyze XR®
Study identifier:CV181-306
ClinicalTrials.gov identifier:NCT01754142
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Kombiglyze XR (Saxagliptin + Metformin XR Fixed Dose Combination) Regulatory Postmarketing Surveillance
Medical condition
Diabetes Mellitus, Type 2
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
755
Study type
Observational
Age
18 Years +
Date
Study Start Date: 24 Nov 2012
Primary Completion Date: 01 Sept 2016
Study Completion Date: 01 Sept 2016
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Aug 2017 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Type 2 diabetes mellitus subjects initiating Kombiglyze XR Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment within the approved indications will be enrolled | - |
Contacts
Investigators
Principal Investigator
Bristol-Myers Squibb
Bristol-Myers Squibb
